Banner
Home
Search by IDs Search by Gene
Browse
Patient Tumour & Clinical details PDX & PDXBiomarker details
Update
With gene expression Without gene expression Mutation & CNV Plot
Summary

Searching Database & Compiling the results...

This process involves analyzing complex genetic data and may take a moment.




PDX model details

PDX ID 201.1A
Host Strain(and Source) NSG
Source: Monash University
Host Strain Immune system Humanized NO
Host Type Testosterone supplemented
Graft Site Subcutaneous
Current Generation
(* indicates number of generations grown in Castrate host)
 42
Average PDX Generation Time (days +/- SEM) 35 ± 2
Tumour preparation Tumor solid
Tumour Characterization Technology Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumour confirmed not to be of Mouse/EBV origin Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed Routine QA every 2-3 passages
Associated meta data
PDX model availability Yes (fixed, frozen)
Governance restriction for distribution Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID 34413304; 30049486
Markers 201.1A
AR Y
PSA Y
PSMA N
NE N
ERG Y
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.

PDX ID Gene Symbol CNV Log2 CNV Copy CNV Call Experiments name Platform Reference genome
201.1A MLH1 -0.817 1.135 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
201.1A PTEN -2.020 0.493 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
201.1A SUFU -2.020 0.493 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
201.1A CDKN1B -0.954 1.032 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
201.1A RB1 -16.849 1.690e-05 Homdel MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
201.1A PTEN -12.233 4.155e-04 Homdel MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
201.1A KMT2A 0.816 3.521 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
201.1A ZFHX3 0.819 3.528 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19

Clinical Information

Sample Number 201.1A
Sample Site Dura
Sample source Autopsy
Pathology Tumour Diagnosis Adenocarcinoma
Gleason Score None
Primary Gleason Score None
Secondary Gleason Score None
Tertiary Gleason Score None
ISUP Grade Group
Tumour Grade
D'Amico Risk Classification
Tumour Volume (in cc) 0.0
Treatment Prior to Specimen Collection ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide

Patient Information

Patient Number 201
Sex Male
Diagnosis Prostate Cancer
PSA at diagnosis (ng/mL) NA
Consent to share data Yes, subject to ethical review

Patient Tumour Collection (Current Model)
Tumour sample ID 201.1A
Patient Age (binned in 5 year age groups) 70-74
This heatmap displays the mutations of curated sequence variants.
Download Plot
The Mut plot is not shown
PDX ID Gene Symbol Total Read Depth Alternate Frequency Consequence Exon GnomAD AF CADD PHRED score ClinVar significance Platform Experiments Name Reference Library Type Instrument Type
201.1A AR 204 1.0 Missense variant '8/8 . 25.3 Pathogenic Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A AR 945 0.99 Missense variant '4/8 . 23.2 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A MLH1 142 0.96 Inframe insertion,splice region variant '10/19 . . - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A MLH1 168 0.82 Splice acceptor variant . . . - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A CACNA1H 107 0.5 Missense variant '9/35 8.90E-05 5.716 Uncertain significance Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A TGFBR2 119 0.5 Frameshift variant '4/8 0.0003621 35 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A CTNNB1 346 0.5 Missense variant '3/15 . 29.9 Pathogenic/likely pathogenic, other Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A MSH2 298 0.49 Missense variant '16/16 6.12E-05 27.7 Uncertain significance Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A KMT2D 1715 0.49 Missense variant '48/54 . 33 Conflicting interpretations of pathogenicity Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A GSK3B 366 0.48 Missense variant '6/12 . 27.4 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A GLI2 368 0.48 Missense variant '14/14 . 24.3 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A SIX3 1013 0.46 Frameshift variant '1/2 0 28.8 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A MUTYH 1218 0.46 Missense variant '13/16 0.0007924 20.7 Conflicting interpretations of pathogenicity Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A KMT2C 208 0.45 Stop gained '36/59 0 40 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A BLM 469 0.45 Frameshift variant '7/22 2.95E-05 . - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A GLI2 1572 0.44 Missense variant '4/14 4.06E-06 29.6 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A AIP 1324 0.44 Missense variant '6/6 . 29.7 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A BRCA2 222 0.42 Frameshift variant '11/28 . . - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A OGDH 139 0.41 Frameshift variant '22/23 . 35 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A SIRT1 42 0.4 Frameshift variant '1/9 . . - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A MSH6 464 0.4 Frameshift variant '4/10 . 24.1 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A TERT 124 0.39 Missense variant '2/16 . 5.144 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A NFE2L1 580 0.38 Frameshift variant '2/6 . . - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A ZFHX3 1418 0.34 Frameshift variant '2/10 . . - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A ASXL1 730 0.34 Frameshift variant '13/13 0.0004861 34 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A BBC3 310 0.34 Frameshift variant '4/4 . . - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
201.1A CTCF 536 0.28 Stop gained '11/12 . 39 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500